RB nr 74/2008

Legal basis: § 5 subpar. 1 pt. 1 of RO and § 7 of RO
The Management Board of MCI Management SA informs that on December 10, 2008 MCI.BioVentures Sp. z o.o. – a subsidiary of MCI Management SA paid in the capital to acquire 1,625 new shares in 24med sp. z o.o. of the nominal value of PLN 100 per each. MCI.BioVentures paid for the purchased shares PLN 2,600,000 in cash that is PLN 1,600 per each share. As a result of the acquisition of new shares MCI.BioVentures holds 80% of the share capital of 24med Sp. z o.o.
The transaction was executed in connection of the fulfillment of the conditions of the investment agreement concluded between MCI.BioVentures and 24med on Sept. 22, 2008 and it complies with the planned execution of the 2nd round of financing.
24med is a company whose operations include providing membership medical services consisting in emergency as well as ambulatory medical aid and imaging diagnostics. The Management Board of MCI Management SA informed about the investment of MCI.BioVentures Sp. z o.o. in 24med Sp. z o.o. in its current report no. 70/2008.
MCI.BioVentures is a seed capital fund investing up to EUR 1 million in companies operating in the sector of biotechnology, new drugs and healthcare in Poland. The funds of the fund shall be spent on investments in companies in their early stage of development.
This is a long-term investment. There are no connections referred to in § 7 subpar. 6 of RO.
The purchased assets represent over 20% of the share capital of 24med Sp. z o.o. and are considered assets of considerable value.